PE 22-28

PE 22-28 — Spadin-Derived TREK-1 Blocker Neuropeptide

PE 22-28 is a synthetic heptapeptide with the sequence Gly-Val-Ser-Trp-Gly-Leu-Arg (GVSWGLR) — the smallest active fragment of spadin, which is itself derived from the propeptide of sortilin (neurotensin receptor-3, NTSR3). It is a research compound of interest for its non-monoaminergic, rapid-acting antidepressant mechanism.

Mechanism of Action

PE 22-28 is a selective blocker of the TREK-1 (K2P2.1 / KCNK2) two-pore-domain potassium channel, with reported IC50 near 0.1 nM for the human channel and selectivity over TREK2, TRAAK, TRESK and TASK1. TREK-1 blockade is studied to enhance serotonergic signaling and activate BDNF/mTOR-linked pathways, producing rapid antidepressant-like effects and increased neurogenesis in preclinical models.

Available Formats

• 10mg

Reconstitution: Reconstitute with Bacteriostatic Water (BAC Water) for multi-use stability, or Sterile Water for single-use protocols. Store lyophilized vials refrigerated at 2–8°C, protected from light.

Key Research Areas

🧠 Depression Research

Produces fast-acting antidepressant-like effects in rodent models (forced swim, novelty-suppressed feeding, learned helplessness) with faster onset than SSRIs.

🧠 Neurogenesis

Associated with increased hippocampal neurogenesis and synaptic markers in mice.

🧠 Neuroprotection

TREK-1 modulation is studied in ischemia and neuroprotection contexts.

🧠 Mood & Cognition

Of broad CNS research interest as a non-monoaminergic antidepressant mechanism.

FOR RESEARCH USE ONLY (RUO). This product is not a drug, food, or cosmetic and is not approved for human or veterinary use. All statements describe proposed or preclinical research findings only. Intended strictly for in vitro and laboratory research by qualified professionals. EhBuddy Peptides assumes no liability for misuse.